Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (12)

2024

  1. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

    Journal of Thoracic Oncology, Vol. 19, Núm. 2, pp. 285-296

2023

  1. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

    Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 1999-2006

  2. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

    Cell Reports Medicine, Vol. 4, Núm. 11

2022

  1. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311

  2. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

    ESMO Open, Vol. 7, Núm. 2

2021

  1. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867

  2. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

    Future Oncology, Vol. 17, Núm. 10, pp. 1165-1184

2017

  1. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

    New England Journal of Medicine, Vol. 377, Núm. 20, pp. 1919-1929

2014

  1. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920

2013

  1. Erratum: The role of pharmacogenomics in metastatic renal cell carcinoma (Cancer and Metastasis Reviews (2012) 31:SUPPL. 1 (S29-S32) DOI: 10.1007/s10555-012-9356-x)

    Cancer and Metastasis Reviews

2012

  1. The role of pharmacogenomics in metastatic renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 31, pp. S29-S32

2011

  1. Brief report: Phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors

    Oncology, Vol. 80, Núm. 3-4, pp. 219-222